http://tinyurl.com/cgqqw
MKC-1 is an orally-active, novel, small molecule, cell cycle inhibitor with a unique mechanism of action. Specifically, MKC-1 arrests cellular mitosis by inhibiting a novel intracellular target important in cellular trafficking that has been shown to be involved in cell division. In preclinical studies, MKC-1 demonstrated impressive activity in a broad range of tumor models. Clinical partial and durable responses have been observed in patients with previously treated NSCLC and metastatic breast cancers. Tested in over 250 patients to date, Miikana plans to initiate two phase II trials with MKC-1 for the treatment of breast cancer and non-small cell lung cancer.
Threaded Mode